All In Biotech

Drug Trial Radar · NCT02311894

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

A Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rDNA Origin) Injection] Administered Daily to Naïve Growth Hormone-Deficient Children (iSTUDY)

Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

Mar 31, 2015

Primary completion

Nov 8, 2017

Study completion Nov 8, 2017

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naïve to prior recombinant human growth hormone (rhGH) treatment. The study is designed to characterize the immunogenicity profile of somatropin (rDNA origin) injection when administered daily subcutaneously for 12 months. The clinical impact of immunogenicity will also be assessed.

Conditions

  • Growth Hormone Deficiency

Interventions

  • SomatropinDrug

    Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1Time frame: Baseline up to 1 year

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital Research Institute

    Little Rock, Arkansas

  • Children'S Hospital of Orange County

    Orange, California

  • Center of Excellence in Diabetes & Endocrinology

    Sacramento, California

  • San Diego Medical Group; Pediatric Endocrinology

    San Diego, California

  • Rocky Mountain Pediatric Endocrinology, PC

    Centennial, Colorado

  • Pediatric Endocrine Associates

    Greenwood Village, Colorado

  • Nemours Children's Clinic - of the Nemours Foundation

    Jacksonville, Florida

  • Miami Children's Hospital

    Miami, Florida

  • Nemours Childrens Clinic

    Orlando, Florida

  • The Pediatric Endocrine Office of Larry C. Deeb

    Tallahassee, Florida

  • Pediatric Endrocine Assoc

    Tampa, Florida

  • USF Diabetes Center

    Tampa, Florida

  • Emory Children's Center

    Atlanta, Georgia

  • University of Louisville

    Louisville, Kentucky

  • Barry J Reiner, MD, LLC

    Baltimore, Maryland

  • Boston Childrens Hospital

    Boston, Massachusetts

  • Baystate Endocrinology and Diabetes; Baystate Children's Specialty Center, Pediatric Endocrinology

    Springfield, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota Childrens' Hospital

    Minneapolis, Minnesota

  • Children's Healthcare d.b.a Children's Hospitals and Clinics of Minnesota

    Saint Paul, Minnesota

  • Children's Mercy Hospitals & Clinics; Pulmonology

    Kansas City, Missouri

  • Hackensack University Medical Center PARTNER

    Hackensack, New Jersey

  • New York Presbyterian Hospital

    New York, New York

  • UNC General Pediatrics Clinic

    Chapel Hill, North Carolina

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • Milton S Hershey Ped Sub Spclt

    Hershey, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Medical University of South Carolina; MUSC Pediatric Endocrinology

    Charleston, South Carolina

  • Endocrine Associates of Dallas

    Dallas, Texas

  • Cook Children's Hospital

    Fort Worth, Texas

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington

  • MultiCare Institute for Research and Innovation

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.